Roots of New Drug for HES Trace Back to Cincinnati Children’s
Post Date: September 28, 2020 | Publish Date:
![](https://scienceblog.cincinnatichildrens.org/wp-content/uploads/2020/09/rothenberg-graphic.jpg)
![](https://scienceblog.cincinnatichildrens.org/wp-content/uploads/2019/06/14_Mark-E-Rothenbergl_ml-4049-e1561657411412.jpg)
In 2008, Marc Rothenberg, MD, PhD, Director of the Division of Allergy and Immunology and the Cincinnati Center for Eosinophilic Disorders at Cincinnati Children’s, led an international group of investigators to conduct a randomized clinical trial that proved the ability of mepolizumab to lower oral steroid doses in patients with HES.